Genentech To Present New Data On Personalized Medicines And Cancer Immunotherapies At The 2017 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data on 20 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, in Chicago. More than 190 abstracts have been accepted, including two “late breakers” and 24 oral presentations.

“We are making significant advances with personalized medicines and cancer immunotherapies,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “With continued research and collaborations, we are striving to develop medicines and combinations, incorporate sophisticated diagnostics and integrate big data in our effort to get closer to the goal of curing cancer.”

Key highlights from the Genentech oncology portfolio include new results from the APHINITY study in early breast cancer and ALEX study in lung cancer. Both of these studies will be highlighted as part of ASCO’s official press program on Monday, June 5. APHINITY is a randomized Phase III study, investigating Perjeta plus Herceptin® (trastuzumab) and chemotherapy as an adjuvant (after surgery) treatment for people with HER2-positive early breast cancer. The APHINITY study was conducted in collaboration with the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS). ALEX is a randomized, multicenter, open-label Phase III study that compared Alecensa and crizotinib in people with previously untreated ALK-positive non-small cell lung cancer (NSCLC).

Back to news